The evolution of insulin treatment in type 1 diabetes: The advent of analogues

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 6, 2004, Pages 378-381

  Gallen, Ian ^a  

^a WYCOMBE HOSPITAL   (United Kingdom)

Author keywords

Glargine; Insulin analogues; Lispro; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 11344273716     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040060301     Document Type: Review

References (17)

1. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Paediatr 1993;125:177-88.
2. Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80.
3. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739-46.
4. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
5. Home PD, Lindholm A, Ris A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2000; 17:762-70.
6. Anderson JH, Jr., Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-70.
7. Chatterjee S, Gallen IW, Sandler L. 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications. Diabetes Care 1999; 22:1226-7.
8. Owens D, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002;56:460-6.
9. Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-42.
10. Ratner RE, Hirsch IB, Neifing JL et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43.
11. Raskin P, Klaff L, Bergenstal R et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71.
12. Pieber TR, Eugene-Jolchine I, Derobert E, The European Study Group of HOE 901 in type 1 diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-62.
13. Ashwell S, Bilous R, Heller S, Hepburn D, Home P. Improvement in over-all blood glucose control with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetologia 2003;A784.
14. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin spart. Diabetes Care 2003;26:590-6.
15. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301.
16. Danne T, Lupke K, Walte K, Von Schetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92.
17. Gallen IW, Carter C. Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes. Practical Diabetes International 2004;21:110-14.